CAR-T cell therapy has become a cornerstone in the immuno-oncology playbook, particularly for hematologic malignancies. But despite significant clinical success, the first generation of CAR-T therapies has yet to reach its full potential—especially in the context of solid tumors, scalability, and safety. As biotech companies...